Premium
Comparison of pre‐ vs. postmeal administration of miglitol for 3 months in type 2 diabetic patients
Author(s) -
Aoki K.,
Nakajima S.,
Nezu U.,
Shinoda K.,
Terauchi Y.
Publication year - 2008
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2008.00960.x
Subject(s) - postprandial , meal , medicine , type 2 diabetes , diabetes mellitus , endocrinology , gastroenterology , adverse effect , zoology , insulin , biology
Aim: α‐Glucosidase inhibitors (αGIs) primarily modify postprandial plasma glucose levels and should be taken just before meals. We previously demonstrated that a single administration of miglitol within 30 min after the start of a meal was equally effective as when administered just before a meal. We here compared pre‐ vs. postmeal administration of miglitol for 3 months in type 2 diabetic patients. Methods: Thirty‐one type 2 diabetic outpatients who had never been treated with insulin injections or αGIs were randomized to two groups: patients in group A were asked to take miglitol just before meals, while patients in group B were asked to take miglitol after meals. We measured 1,5‐anhydroglucitol (1,5‐AG) and HbA 1C levels in these patients. Results: The administration of miglitol after meals for a 3‐month period decreased HbA 1C and increased 1,5‐AG levels to the same extent as when administered just before meals. The incidence of adverse effects seemed to be unrelated to the timing of the miglitol administration. Conclusions: Our results suggest that if patients have difficulty remembering to take miglitol just before meal, they should be instructed to take the medicine together with other medicine(s) after the meal; this instruction may improve the treatment compliance of diabetic patients.